NCT00005037View on ClinicalTrials.gov

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

October 31, 2002

Study Completion Date

April 30, 2008

Conditions
Lung Cancer
Interventions
DRUG

temozolomide

DRUG

Temozolomide

Temozolomide capsule once a day for 42 days every 10 weeks.

Trial Locations (2)

19111

Fox Chase Cancer Center, Philadelphia

53188

Waukesha Memorial Hospital, Waukesha

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER

NCT00005037 - Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter